"central" CB 1 receptor, mostly expressed in brain and responsible for cannabinoid psychoactivity (18) , and the "peripheral" CB 2 receptor, mostly expressed in the immune system and unrelated to cannabinoid psychoactivity (19) . Marijuana and its derivatives have been used in medicine for many centuries, and currently there is a renaissance in the study of the therapeutic effects of cannabinoids, which constitutes a widely debated issue with ample scientific and social relevance. Ongoing research is determining whether cannabinoid ligands may be effective agents in the treatment of, for example, pain and inflammation, neurodegenerative disorders such as multiple sclerosis and Parkinson's disease, and the wasting and emesis associated with AIDS and cancer chemotherapy (13) (14) (15) . In addition, cannabinoids may be potential antitumoral agents owing to their ability to induce the regression of various types of tumors, including lung adenocarcinoma (20) , glioma (21, 22) , and thyroid epithelioma (23) in animal models. Although cannabinoids directly induce apoptosis or cell cycle arrest in different transformed cells in vitro (24) , the involvement of this and other potential mechanisms (e.g., inhibition of tumor angiogenesis) in their antitumoral action in vivo is as yet unknown.
This background prompted us to explore whether (a) the skin and skin tumors express cannabinoid receptors; (b) cannabinoid receptor activation exerts a growth-inhibiting action on skin tumors in vivo; and (c) inhibition of angiogenesis is implicated in the antitumoral effect of cannabinoids. Our data show that (a) CB 1 and CB 2 receptors are present in the skin and skin tumors; (b) local cannabinoid receptor activation induces the regression of skin tumors in vivo; and (c) at least two mechanisms may be involved in this action: direct apoptosis of tumor cells and inhibition of tumor angiogenesis.
Methods
Cannabinoids. JWH-133 was prepared in J.W. Huffman's laboratory (25) . WIN-55,212-2 was from Sigma-Aldrich (St. Louis, Missouri, USA). SR141716 and SR144528 were kindly given by Sanofi-Synthelabo (Montpellier, France).
Cell culture. The mouse tumorigenic epidermal cell lines PDV.C57 and HaCa4, and the nontransformed epidermal cell lines MCA3D (mouse) and HaCat (human), were routinely maintained in DMEM supplemented with 10% FCS. Twenty-four hours before the experiments, cells were transferred to low serum (0.5%) DMEM. Primary human keratinocytes (Biowhittaker Europe SPRL, Vervier, Belgium) were grown and cultured for the experiments in KGM-2 medium (Biowhittaker Europe SPRL). Stock solutions of cannabinoid ligands were prepared in DMSO. Control incubations had the corresponding DMSO content. No significant influence of DMSO was observed on cell viability at the final concentration used (0.1-0.2%, vol/vol).
Human tumor samples. Formalin-fixed, paraffinembedded, human tumor samples were obtained from the files of the Department of Pathology, Hospital General de Móstoles (Madrid, Spain). Six-micrometer tumor sections were stained with either hematoxylineosin or used for immunohistochemistry (see below). The normal skin sample ( Figures 1 and 3 , skin) came from the face of a 70-year-old man. The slowly growing tumor sample ( Figure 3 , BCC) came from the face of a 69-year-old woman. The histological analysis revealed the growth of basaloid cell solid nests at the dermoepidermal junction with diagnostic characteristics of basal cell carcinoma. The highly malignant tumor sample ( Figures 1 and 3 , SCC) came from the retroauricular skin of a 73-year-old man. The histological analysis showed the neoplastic growth of epithelial cells, with squamous differentiation and focal areas of acantholysis.
Tumor induction in mice. Malignant skin tumors were induced in nude (NMRI nu) mice by subcutaneous flank inoculation of 10 6 PDV.C57 epidermal tumor cells. When tumors had reached an average volume of 500 mm 3 (range, 400-600 mm 3 ), a continuous flow pump (Alzet 2002; Alza Corporation, Palo Alto, California, USA) was surgically implanted on the flank of every mouse near the site of tumor inoculation. The pump was filled with either vehicle, 1,580 µg of WIN-55,212-2, or 1,580 µg of JWH-133 in 236 µl PBS supplemented with 5 mg/ml BSA and operated at a flux of 0.52 µl/h for 11 days. Tumors were measured with an external caliper and their volume calculated as (4π/3) × (width/2) 2 × (length/2). Cannabinoid treatment did not affect animal weight gain (data not shown).
Viability and apoptosis in vitro. Cell viability in the cultures was determined by the 3-4,5-dimethylthiazol-2,5diphenyltetrazolium bromide thiazol blue test. Apoptosis was determined by both TUNEL staining (21) and oligonucleosomal DNA fragmentation (26) according to kit manufacturer's instructions (Boehringer Mannheim GmbH, Mannheim, Germany).
Proliferation and apoptosis in vivo. For proliferation assays, mice received an intraperitoneal injection of BrdU (120 mg/kg body weight) (Boehringer Mannheim GmbH) 2 hours before tumor harvesting. Detection of BrdU-positive cells was performed using an anti-BrdU mouse mAb (Boehringer Mannheim GmbH) as described (9) . Apoptosis was determined by TUNEL staining (Boehringer Mannheim GmbH) according to kit manufacturer's instructions (21) . Western blot analysis. Particulate cell or tissue fractions were subjected to SDS-PAGE, and proteins were transferred from the gels onto polyvinylidene fluoride membranes. To determine cannabinoid receptor expression the blots were incubated with polyclonal Ab's raised in rabbits against residues 1-14 of the human/mouse CB 1 receptor (1:500; kindly given by A. Howlett, North Carolina Central University, Durham, North Carolina, USA) or residues 20-33 of the human/mouse CB 2 receptor (1:2,000; Cayman Chemical, Ann Arbor, Michigan, USA) as described (21) . Antigen preabsorption experiments were performed by preincubating (37°C, 1 hour) 1 µl (= 0.5 µg) of the anti-CB 1 or anti-CB 2 Ab and 100 µl PBS with or without 20 µl (= 20 µg) of the corresponding immune peptide (Cayman Chemical). Western blots were subsequently done with the aforementioned Ab dilutions. To determine EGF-R phosphorylation the blots were incubated with antiphosphotyrosine (1:500; 4G10 mAb; Upstate Biotechnology Inc., Lake Placid, New York, USA) or anti-keratin 5 (1:1,000; Berkeley Antibody Co., Richmond, California, USA) Ab's, the latter used as a loading control. In all cases, samples were subjected to luminography with an enhanced chemiluminescence detection kit (Amersham Life Sciences, Arlington Heights, Illinois, USA). Densitometric analysis of the blots was performed with the Molecular Analyst software package (Bio-Rad Laboratories Inc., Hercules, California, USA).
Immunohistochemistry. Tissues were fixed in 10% buffered formalin and embedded in paraffin. Sections of mouse and human skin and tumors were stained with the aforementioned Ab's against CB 1 (1:300) and CB 2 (1:300) receptors. Control immunostainings using the secondary Ab in the absence of the primary Ab were routinely performed. In addition, antigen preabsorption experiments were carried out with the corresponding blocking peptides as described above. Immunodetection of blood vessels in cryosections of mouse tumors was performed with an anti-CD31 Ab (1:40; PharMingen, San Diego, California, USA). Sections were incubated with a biotinylated anti-rabbit (CB 1 and CB 2 ) or anti-rat Ab (CD31) and then with peroxidase-conjugated streptavidin (LSAB Kit Peroxidase; DAKO A/S, Glostrup, Denmark). Ab localization was determined using 3,3′-diaminobenzidine (Vector Laboratories, Burlingame, California, USA). Morphometric values were obtained by examination of six 0.11-mm 2 sections per tumor with the image analysis system Leica Qwin (Leica Microsystems Inc., Chantilly, Virginia, USA).
Northern blot analysis. Total RNA was extracted from the tumor samples by the acid guanidinium method (27) . The VEGF probe has been described previously (7) . The placental growth factor (PIGF) probe was kindly given by G. Persico (Istituto Internazionale di Genetica e Biofisica, Naples, Italy). Probes for angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) detection were kindly provided by G.D. Yancopoulos (Regeneron Pharma-ceuticals, Tarrytown, New York, USA). A 1-kb fragment of the 5′ region of the hEGF-R cDNA was used as probe for EGF-R detection (9) . Ribosomal 7S RNA was used as a loading control. Densitometric analysis of the blots was performed with a PhosphorImager using Quantity One software (Bio-Rad Laboratories Inc.).
Statistics. Results shown represent means ± SD. Statistical analysis was performed by ANOVA with a post hoc analysis by the Student-Neuman-Keuls test. Data in Table 1 , Figure 5a , and Figure 6c were analyzed by the Mann-Whitney (Wilcoxon) W test to compare medians for nonparametric data.
Results
Cannabinoid receptors are expressed in skin and skin tumors. The expression of cannabinoid receptors in epidermal cell lines, normal skin, and skin tumors of mice and humans was examined by Western blot analysis and immunohistochemistry. Western blot experiments showed that CB 1 and CB 2 receptors were expressed in a number of tumorigenic and nontransformed epidermal cell lines of murine and human origin ( Figure 1a ). In addition, the two receptors were present in normal mouse skin as well as in benign (papillomas) and malign (squamous cell carcinomas) mouse skin tumors. Likewise, CB 1 and CB 2 receptors were expressed in human skin, keratinocytes, and carcinomas ( Figure 1a ). To ascertain the specificity of the cannabinoid receptor Ab's used in the blotting experi- ments, antigen preabsorption experiments were carried out with the corresponding blocking peptides. As shown in Figure 1b , the peptides blocked anti-CB 1 and anti-CB 2 Ab binding, not only in skin-derived samples but also in other cell types used as well-established controls for the presence of CB 1 (rat cortical neurons) (18), CB 2 (human promyelocytic HL60 cells) (19) , and CB 1 plus CB 2 (rat C6 glioma cells) (21) .
Immunocytochemical analyses showed that in mouse (Figure 2a ) and human (Figure 3a ) normal skin CB 1 and CB 2 receptors were mostly present in suprabasal layers of the epidermis and hair follicles. Basal staining was also observed in some sporadic regions. CB 1 and CB 2 receptor immunoreactivity was also evident in both papillomas and squamous cell carcinomas of mouse origin (Figure 2a ), as well as in human basal cell carcinomas and squamous cell carcinomas (Figure 3a) . The specificity of the immunolabeling was shown by experiments in which the primary Ab was omitted and-as mentioned above for Western blots-by antigen preabsorption experiments carried out with the corresponding blocking peptides (Figures 2b and 3b) . effect of selective receptor antagonists was studied. Thus, the CB 1 antagonist SR141716 and the CB 2 antagonist SR144528 prevented WIN-55,212-2induced apoptosis of PDV.C57 cells (Figures 4, a, c, and  d) , pointing to the involvement of both receptors in the apoptotic action of cannabinoids. Cannabinoids inhibit skin tumor growth in vivo. Given the inhibition of tumorigenic epidermal cell survival in culture by cannabinoids, we evaluated the effect of cannabinoid treatment on skin tumor growth in vivo. Tumors generated by inoculation of the highly malignant PDV.C57 cell line were treated with vehicle or WIN-55,212-2. As shown in Figure 5 , a-c, cannabinoid administration blocked the growth of tumor cells in vivo (in ≈75% of the mice treated).
Because cannabinoid-based therapeutic strategies should be as devoid as possible of psychotropic side effects and PDV.C57 express functional CB 2 receptors, we administered to mice the selective CB 2 agonist JWH-133. Previously, we have provided pharmacological, biochemical, and behavioral evidence that JWH-133 activates selectively the CB 2 receptor and does not elicit psychotropic effects in mice (22) . As shown in Figure  5 , a-c, tumors from JWH-133-treated animals were significantly smaller than those from vehicle-treated controls (in ≈70% of the mice treated).
We next examined whether, as occurs in cultured skin tumor cell lines, cannabinoids induce apoptosis of malignant cells in vivo. As shown in Table 1 , quantification of apoptotic cells in tumor sections revealed that treatment with WIN-55,212-2 or JWH-133 increased the number of apoptotic cells. In contrast, the proliferation index did not significantly differ between control and cannabinoid-treated carcinomas.
Cannabinoids inhibit skin tumor angiogenesis in vivo. Tumors require an adequate supply of oxygen and nutrients to grow more than a few millimeters. For that purpose they produce proangiogenic factors that promote the formation of new blood vessels (28, 29) . We therefore analyzed whether the vascularization of growth-arrested cannabinoid-treated tumors was affected. Northern blot analyses showed that the expression of major proangiogenic factors, namely VEGF, PIGF, and Ang2, was strongly depressed by treatment with WIN-55,212-2 or JWH-133 ( Figure 6a ). The mRNA expression of Ang1 and the two antiangiogenic factors, thrombospondin 1 and thrombospondin 2, was not significantly affected by cannabinoid administration (data not shown). Furthermore, although immunostaining of CD31, a marker of endothelial cells, revealed no significant differences in vascular density (number of blood vessels per unit area) between control and WIN-55,212-2-or JWH-133-treated tumors (Figures 6, b and c), important differences were observed when vessel morphology was examined: while control carcinomas showed a network of dilated vessels, cannabinoid-treated tumors displayed a pattern of blood vessels characterized predominantly by narrow capillaries (Figure 6b ). Morphometric analyses con-firmed that cannabinoid treatment induced a statistically significant decrease in blood vessel size, as determined by the total area occupied by vessels, the area per vessel, and the vessel larger diameter length (Figure 6c ).
Cannabinoids decrease EGF-R activation in skin tumors in vivo.
We have recently found that in skin carcinomas EGF-R plays an important role in triggering the angiogenic switch necessary for skin tumor growth (9) . Thus, we measured the expression levels and activation state of EGF-R in control and cannabinoid-treated skin tumors. While EGF-R mRNA was highly expressed in vehicletreated tumors, in line with its known overexpression in skin carcinomas (30, 31) , the levels of EGF-R mRNA in cannabinoid-treated tumors were very low (Figure 7a ). In addition, the degree of EGF-R activation (autophosphorylation) was markedly reduced in cannabinoidtreated tumors (Figure 7b ). Moreover, exposure of cul-
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The tured PDV.C57 cells to WIN-55,212-2 or JWH-133 blunted EGF-R phosphorylation (Figure 7c ), supporting the direct impact of cannabinoids on skin tumor cells.
Discussion
Here we report that CB 1 and CB 2 cannabinoid receptors are expressed in normal epidermis and in skin tumors and that both receptors are functional in the induction of apoptosis of skin tumor cells and the regression of skin carcinomas. It is therefore plausible that apoptosis of tumor cells and tumor regression are two causally related events. Nonetheless, our data indicate that cannabinoid antitumoral action may also rely on the inhibition of tumor angiogenesis. It has been shown that mouse skin tumor growth and progression depends on critical events leading to epithelial and stromal changes, including the establishment of an active angiogenesis (4) . Here, we report that blood vessels developed by cannabinoid-treated carcinomas are small, in line with the finding that blood vessel enlargement constitutes a prominent feature of skin tumor progression (4, 32) . Moreover, we show that in cannabinoid-treated carcinomas the expression of proangiogenic factors is depressed and that of antiangiogenic factors is unchanged, which fits well with the observations that link skin carcinoma development with a clear imbalance toward positive angiogenic-factor action (6, 7, 9) . Ha-ras activation seems to be a critical event in mouse skin tumor initiation as well as a major component of the angiogenic response (6) in which VEGF plays a pivotal role (5, 9) . Ha-ras activation induces VEGF expression in mouse keratinocytes (6), as well as in other cell types (33, 34) . Our data also show that cannabinoid treatment decreases the expression of PIGF (another VEGF family member) and Ang2, and these two proangiogenic factors may act in concert with VEGF because their expression is highly increased since the early stages of tumor development (9, 28, 29) . EGF-R participates in the regulation of key epidermal functions (35) (36) (37) (38) . Moreover, we have shown that in mouse skin carcinomas EGF-R-dependent Ha-ras activation plays a pivotal role in VEGF expression and tumor angiogenesis and growth (9) . Carcinoma growth arising from subcutaneous injection of tumor epidermal cells is a biphasic process. The first phase of slow growth occurs independently of EGF-R function. Later, an angiogenic switch response mediated by the EGF-R seems to be an essential requirement for complete tumor growth, involving high VEGF levels. Other members of the EGF-R family such as HER2 may also exert their relevant anticarcinogenic role via modulation of angiogenesis (39) . Here we show that cannabinoid treatment impairs EGF-R function, VEGF expression, and angiogenesis in skin tumors. It is of interest that inhibition of EGF-R function also occurred upon exposure of cultured skin tumor cells to cannabinoids, indicating that the changes observed in EGF-R activity in vivo reflect a direct impact of cannabinoids on tumor cells and are not a mere consequence of decreased tumor size. Although at present we cannot establish the mechanism for the decrease of EGF-R phosphorylation in cannabinoid-treated tumors, it is tempting to speculate that cannabinoid treatment interferes with the tumor angiogenic switch and that this, together with the direct induction of apoptosis on tumor cells, is a reason for the inhibition of tumor growth in our system.
Nonmelanoma skin cancer is one of the most common malignancies in humans. Different types of strategies are currently being investigated as therapies for the treatment of these tumors, including cryotherapy, topical chemotherapeutic agents such as 5-fluorouracil, and photodynamics, the success of which is hampered by limitations such as the poor penetration of molecules into the skin and the difficulty of gaining access to the whole tumor (10) (11) (12) . The present data indicate that local cannabinoid administration may constitute an alternative therapeutic approach for the treatment of nonmelanoma skin cancer. Of further therapeutic interest, we show that skin cells express functional CB 2 receptors. The synergy between CB 1 and CB 2 receptors in eliciting skin tumor cell apoptosis reported here is nonetheless intriguing because it is not observed in the case of cannabinoid-induced glioma cell apoptosis (21, 22) . In any event, the present report, together with the implication of CB 2 -or CB 2 -like receptors in the control of peripheral pain (40) (41) (42) and inflammation (41) , opens the attractive possibility of finding cannabinoidbased therapeutic strategies for diseases of the skin and other tissues devoid of nondesired CB 1 -mediated psychotropic side effects.
